PURPOSE: To describe the clinical outcomes of a compulsory switch from branded to generic levetiracetam (LEV) among people with epilepsy (PWE) in an outpatient setting. METHODS: We conducted a retrospective chart review of 760 unduplicated consecutive adult patients attending a tertiary care epilepsy clinic at Ben Taub General Hospital. On November 1, 2008 hospital policy required all patients receiving branded LEV to be automatically switched to generic LEV. We calculated the proportion of patients switching back to branded LEV and reasons for the switch back. KEY FINDINGS: Of the 260 patients (34%) being prescribed LEV (generic and brand name) during the study period, 105 (42.9%) were switched back to brand name LEV by their treating physicians. Reasons for switch back included increase in seizure frequency (19.6% vs. 1.6%; p < 0.0001) and adverse effects (AEs) (3.3%). AEs included headache, fatigue, and aggression. Patient age was associated with switchback when controlling for gender, epilepsy classification, and treatment characteristics [relative risk (RR) 2.44; 95% confidence interval (CI) 2.09-2.84; p < 0.05)]. An increase in seizure frequency subsequent to generic substitution was associated with polytherapy compared to monotherapy (3.225; 1.512-6.880; p < 0.05). SIGNIFICANCE: A significant proportion of patients in our cohort on generic LEV required switch back to the branded drug. Careful monitoring is imperative because a compulsory switch from branded to generic LEV may lead to poor clinical outcomes, with risk of AEs and increased seizure frequency. Wiley Periodicals, Inc.
PURPOSE: To describe the clinical outcomes of a compulsory switch from branded to generic levetiracetam (LEV) among people with epilepsy (PWE) in an outpatient setting. METHODS: We conducted a retrospective chart review of 760 unduplicated consecutive adult patients attending a tertiary care epilepsy clinic at Ben Taub General Hospital. On November 1, 2008 hospital policy required all patients receiving branded LEV to be automatically switched to generic LEV. We calculated the proportion of patients switching back to branded LEV and reasons for the switch back. KEY FINDINGS: Of the 260 patients (34%) being prescribed LEV (generic and brand name) during the study period, 105 (42.9%) were switched back to brand nameLEV by their treating physicians. Reasons for switch back included increase in seizure frequency (19.6% vs. 1.6%; p < 0.0001) and adverse effects (AEs) (3.3%). AEs included headache, fatigue, and aggression. Patient age was associated with switchback when controlling for gender, epilepsy classification, and treatment characteristics [relative risk (RR) 2.44; 95% confidence interval (CI) 2.09-2.84; p < 0.05)]. An increase in seizure frequency subsequent to generic substitution was associated with polytherapy compared to monotherapy (3.225; 1.512-6.880; p < 0.05). SIGNIFICANCE: A significant proportion of patients in our cohort on generic LEV required switch back to the branded drug. Careful monitoring is imperative because a compulsory switch from branded to generic LEV may lead to poor clinical outcomes, with risk of AEs and increased seizure frequency. Wiley Periodicals, Inc.
Authors: Luigi Maria Specchio; Antonio Gambardella; Anna Teresa Giallonardo; Roberto Michelucci; Nicola Specchio; Giovanni Boero; Angela La Neve Journal: Epilepsy Res Date: 2006-06-30 Impact factor: 3.045
Authors: Nitin K Sethi; Josh Torgovnick; Prahlad K Sethi; Edward Arsura; Pierre Emmanuel Paradis; Mei S Duh; Michael B Durkin; George J Wan Journal: Neurology Date: 2010-02-23 Impact factor: 9.910
Authors: D M Labiner; P E Paradis; R Manjunath; M S Duh; M-H Lafeuille; D Latrémouille-Viau; P Lefebvre; S L Helmers Journal: Neurology Date: 2010-04-14 Impact factor: 9.910
Authors: Maria Stella Vari; Francesca Pinto; Elisabetta Mencaroni; Giovanna Giudizioso; Carlo Minetti; Angela La Neve; Tiziana Francavilla; Marta Piccioli; Salvatore Striano; Luigi del Gaudio; Pierangelo Tovo; Pasquale Striano; Alberto Verrotti Journal: Clin Drug Investig Date: 2016-01 Impact factor: 2.859
Authors: Paul Boon; Sebastiaan Engelborghs; Henri Hauman; An Jansen; Lieven Lagae; Benjamin Legros; Michel Ossemann; Bernard Sadzot; Katrien Smets; Etienne Urbain; Kenou van Rijckevorsel Journal: Acta Neurol Belg Date: 2012-04-28 Impact factor: 2.396
Authors: H Gothe; I Schall; K Saverno; M Mitrovic; A Luzak; D Brixner; U Siebert Journal: Appl Health Econ Health Policy Date: 2015-08 Impact factor: 2.561